Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma.

Trial Profile

Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Erlotinib (Primary) ; Sorafenib (Primary)
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Mar 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Nov 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top